PD-1 antibodies either as precision medicine informed monotherapy or combinations are transforming cancer care
Wednesday, March 31, 2021 2:00 PM to 2:20 PM · 20 min. (Africa/Abidjan)
Immunotherapy
Keynotes: Antibodies & Immunotherapy plenary
Presentation
Information
Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck
